---
ID: P92
Title: Liquid Biopsy Surveillance Architect
Registry: CLAI-OS Precision Engine (P-series)
License: Open documentation release (prompt body withheld for validation)
Version: 1.0.0
Author: Dr. Christabel Odeta — SAVANT FRAMEWORK · CLAI-OS · AEGIS-GLOBAL
Last Updated: 2026-10-12
---

# P92: Liquid Biopsy Surveillance Architect

## Abstract

Conventional oncology surveillance detects recurrence only after sufficient cellular proliferation generates anatomically visible disease burden; by that time, clonal expansion, resistance evolution, immune escape, and metastatic dissemination may be biologically entrenched. P92 shifts surveillance from morphology-based detection toward molecular kinetics-based anticipation using circulating tumor DNA, circulating tumor cells, exosomal RNA, methylation signatures, fragmentomics, and proteogenomic biomarkers.

> Prompt body: WITHHELD. This is an open documentation release — abstract, methodology, and merits — published so the design can be examined and validated.

## Methodology

**Design objectives**

- Tumor-informed ctDNA surveillance at 0.01% variant-allele-fraction sensitivity and tumor-naive methylation platforms at 0.1% VAF sensitivity for minimal residual disease detection.
- Resistance evolution detection monitoring secondary mutations, bypass pathway activation, copy-number amplification, and lineage transformation (for example EGFR T790M-to-C797S, ALK G1202R, ESR1 mutation, KRAS amplification, BRAF amplification).
- Clonal hematopoiesis discrimination via matched leukocyte sequencing, fragmentomic differentiation, and methylation context, to prevent false relapse labeling and overtreatment.
- Immunotherapy response modeling that differentiates pseudoprogression, hyperprogression, inflammatory flare, and true progression through ctDNA kinetics, cytokine signatures, and T-cell repertoire expansion.
- Sickle-cell-specific adaptation recalibrating baseline cell-free DNA expectations, inflammatory background thresholds, and endothelial injury signatures for accurate molecular surveillance under chronic hemolysis.

**Methodological innovation**

- Molecular Kinetic Observatory: continuous analysis of variant-allele-fraction trajectories, molecular half-life estimation, clearance slope analysis, and exponential decay modeling rather than episodic binary detection.
- Temporal Advantage Architecture: surveillance frequency adjusts dynamically to tumor biology, recurrence risk, prior molecular trajectory, treatment intensity, and historical clearance kinetics.
- Fragmentomics and epigenetic surveillance beyond mutation tracking: fragment length distributions, nucleosome positioning, methylation signatures, and tissue-of-origin inference for occult primary identification and inflammatory-versus-neoplastic differentiation.

**Key performance indicators**

- Months gained before radiographic progression
- Resistance mutation detection lead time
- False-positive rate (clonal hematopoiesis discrimination accuracy)
- Pseudoprogression identification accuracy
- Sickle-cell-specific calibration validity

**Integration**

- Upstream: P91 (Genomic Variant Actionability Arbiter) for baseline variant characterization.
- Downstream: P93 (Immune Evasion & Microenvironment Profiler) for microenvironment response prediction; P94 (Minimal Residual Disease in Hematologic Malignancy) for marrow-based molecular correlation.

## Merits

- Enables intervention months before conventional imaging detects recurrence, preserving curative treatment windows.
- Monitors ctDNA recurrence dynamics and forecasts resistance evolution before clinical progression.
- Distinguishes clonal hematopoiesis from malignant recurrence, reducing false relapse labeling and overtreatment.
- Generates adaptive surveillance schedules and escalates therapy at molecular progression stages rather than radiographic ones.
- Reduces late-stage treatment burden by compressing the interval between molecular signal and therapeutic action.

## Guidance for Use

This document records the design intent and scientific rationale of P92 (Liquid Biopsy Surveillance Architect) as published in the CLAI-OS Tier III (Savant Precision Engine, P91–P110) compendium. The executable prompt body is withheld; nothing in this file is sufficient to operate the module. The material is released openly so that the design can be examined, critiqued, and independently validated.

Appropriate use:

- Scientific review, replication design, and methodological critique by researchers and validation groups.
- Reference for integration planning across the P-series registry.
- Citation in scholarly or institutional work describing the CLAI-OS Precision Engine.

Limitations:

- This is not a medical device, a clinical decision-support product, or a standard of care. Nothing in this document may be used to direct diagnosis, treatment, dosing, or triage for any patient.
- Genomic and oncology statements reflect only the claims made in the source compendium; publication of this documentation does not constitute independent clinical validation.
- Sensitivity figures (0.01% and 0.1% VAF) are the design targets stated in the source compendium, not validated performance claims.

---

C0 informational classification; confers no clinical, legal, financial, or safety authority.
